Anidulafungin: A novel echinocandin

Therapy

Volumn 3, Issue 1, 2006, Pages 39-54

  Vasquez, José A ^a  

^a HENRY FORD HOSPITAL   (United States)

Author keywords

Anidulafungin; Antifungal; Aspergillosis; Candidemia; Candidiasis; Echinocandin

Indexed keywords

ALANINE AMINOTRANSFERASE; AMPHOTERICIN; AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ASPARTATE AMINOTRANSFERASE; CARBAMAZEPINE; CASPOFUNGIN; CYCLOSPORIN; DEXAMETHASONE; ECHINOCANDIN; FLUCONAZOLE; GAMMA GLUTAMYLTRANSFERASE; ITRACONAZOLE; MICAFUNGIN; POSACONAZOLE; PYRROLE DERIVATIVE; RIFAMPICIN; TACROLIMUS; VORICONAZOLE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ANAPHYLAXIS; ANTIBIOTIC RESISTANCE; ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLOSIS; ASPERGILLUS; BLOOD DISEASE; CANDIDA; CANDIDIASIS; CLINICAL TRIAL; DIGESTIVE SYSTEM DISEASE; DIZZINESS; DOSE RESPONSE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG DEGRADATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG FEVER; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TRANSFORMATION; DYSPEPSIA; DYSPNEA; ESOPHAGUS CANDIDIASIS; FEBRILE NEUTROPENIA; FLUSHING; HEADACHE; HUMAN; HYPOKALEMIA; HYPOTENSION; IMMUNE DEFICIENCY; IN VITRO STUDY; KIDNEY FAILURE; LEUKOPENIA; LIVER DYSFUNCTION; LIVER FAILURE; LIVER TOXICITY; LYMPHATIC SYSTEM DISEASE; MINIMUM INHIBITORY CONCENTRATION; MORBIDITY; MORTALITY; MYCOSIS; NAUSEA; NEPHROTOXICITY; NEUROLOGIC DISEASE; NEUTROPENIA; NONHUMAN; PHARMACODYNAMICS; PHLEBITIS; RACE; SEIZURE; SKIN MANIFESTATION; SYSTEMIC MYCOSIS; THROMBOPHLEBITIS; THRUSH; VASCULAR DISEASE; VOMITING;

EID: 33646167834     PISSN: 14750708     EISSN: 1744831X     Source Type: Journal    
DOI: 10.1586/14750708.3.1.39     Document Type: Article

References (78)

1. McNeil MM, Nash SL, Hajjeh RA et al. Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. Clin. Infect. Dis. 33, 241-647 (2001).
2. Blignaut E, Messer S, Hollis RJ, Pfaller MA. Antifungal susceptibility of South African oral yeast isolates from HIV/AIDS patients and healthy idividuals. Diagn. Microbiol. Infect. Dis. 44, 269-274 (2002).
3. Vazquez JA. Therapeutic options for the management of oropharyngeal and esophageal candidiasis in HIV/AIDS patients. HIV Clin. Trials 1, 27-59 (2000).
4. Samaranayake LP. Oral mycoses in HIV infection. Oral Surg. Oral Med. Oral Pathol. 73, 271-280 (1992).
5. Denning DW. Therapeutic outcome in invasive aspergillosis. Clin. Infect. Dis. 23, 208-615 (1996).
6. Denning DW. Invasive aspergillosis. Clin. Infect. Dis. 26, 281-803 (1998).
7. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin. Infect. Dis. 32, 258-366 (2001).
8. Wingard JR, Leather H. A new era of antifungal therapy. Biol. Blood Marrow Transplant. 10, 23-90 (2004).
9. Hajjeh RA. Sofair AN, Harrison LH et al. Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. J. Clin. Microbiol. 42, 2519-1527 (2004).
10. Trick WE, Fridkin SK, Edwards JR et al. for the National Nosocomial Infections Surveillance System Hospitals. Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin. Infect. Dis. 35, 227-630 (2002).
11. Singh N. Changing spectrum of invasive candidiasis and its therapeutic implications. Clin. Microbiol. Infect. 7(Suppl.2), 1-7 (2001).
12. Ostrosky-Zeichner L, Rex JH, Pappas PG et al. Antifungal susceptibility survey of 2000 bloodstream Candida Isolates in the United States. Antimicrob. Agents Chemother. 47, 2149-3154 (2003).
13. Rex JH, Walsh TJ, Sobel JD et al. for the Infectious Diseases Society of America. Practice guidelines for the treatment of candidiasis. Clin. Infect. Dis. 30, 262-678 (2000).
14. Pappas PG, Rex JH, Lee J et al. for the NIAID Mycoses Study Group. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin. Infect. Dis. 37, 234-643 (2003).
15. Bates DW, Su L, Yu DT et al. Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin. Infect. Dis. 32, 286-693 (2001).
16. Wingard JR, Kubilis P, Lee L et al. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin. Infect. Dis. 29, 2402-1407 (1999).
17. Fromtling RA. Human mycoses and advances in antifungal therapy. Drug News Perspect. 14, 281-292 (2001).
18. Ally R, Schurmann D, Kreisel W et al. for the Esophageal Candidiasis Study Group. A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin. Infect. Dis. 33, 2447-1454 (2001).
19. Barbaro G, Barbarini G, Calderon W et al. Fluconazole versus itraconazole for Candida esophagitis in acquired immunodeficiency syndrome. Gastroenterology 111, 2169-1177 (1996).
20. Denning DW. Echinocandin antifungal drugs. Lancet 362, 2142-2151 (2003).
21. Morrison VA. The role of caspofungin and the echinocandins in the antifungal armamentarium. Curr. Opin. Invest. Drugs 3, 2432-2436 (2002).
22. Ostrosky-Zeichner L, Rex JH, Pappas PG et al. Antifungal susceptibility survey of 2,000 bloodstream isolates in the United States. Antimicrob. Agent Chemother. 47, 2149-2154 (2003).
23. Messer SA, Kirby JT, Sader HS, Fritsche TR, Jones RN. Initial results from a longitudinal international surveillance programme for anidulafungin (2003). J. Antimicrob. Chemother. 54, 2051-2056 (2004).
24. Pfaller MA, Boyken L, Hollis RJ, Messer SA, Tendolkar S, Diekema DJ. In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole. J. Clin. Microbiol. 43, 2425-2427 (2005).
25. Ernst ME, Klepser ME, Wolfe EJ, Pfaller MA. Antifungal dynamics of LY 303366, an investigational echinocandin B analog, against Candida spp. Diagn. Microbiol. Infect. Dis. 26, 225-231 (1996).
26. Espinel-Ingroff A. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY-303366 against opportunistic filamentous and dimorphic fungi and yeasts. J. Clin. Microbiol. 36, 2950-2956 (1998).
27. Johnson EM, Goldstein BP, Davey KG, Fraser MA. Comparison of the in vitro activity of anidulafungin with amphotericin B, caspofungin, fluconazole, itraconazole and voriconazole against a panel of 780 yeasts obtained from five European centres. Presented at: The 14th European Congress of Clinical Microbiology and Infectious Diseases, May 1-4, Prague, Czech Republic. Abstract 513 (2004).
28. Uzun O, Kocagoz S, Cetinkaya Y et al. In vitro activity of a new echinocandin, LY-303366, compared with those of amphotericin B and fluconazole against clinical yeast isolates. Antimicrob. Agents Chemother. 41, 2156-2157 (1997).
29. Zhanel GG, Karlowsky JA, Zelenitsky SA et al. Susceptibilities of Candida species isolated from the lower gastrointestinal tracts of high-risk patients to the new semisynthetic echinocandin LY-303366 and other antifungal agents. Antimicrob. Agents Chemother. 42, 2446-2448 (1998).
30. Zhanel GG, Karlowsky JA, Harding GA et al. In vitro activity of a new semisynthetic echinocandin, LY-303366, against systemic isolates of Candida species, Cryptococcus neoformans, Blastomyces dermatitidis and Aspergillus species. Antimicrob. Agents Chemother. 41, 263-865 (1997).
31. Marco F, Pfaller MA, Messer SA, Jones RN. Activity of MK-0991 (L-743,872), a new echinocandin, compared with those of LY-303366 and four other antifungal agents tested against bloodstream isolates of Candida spp. Diagn. Microbiol. Infect. Dis. 32, 23-37 (1998).
32. Pfaller MA, Messer SA, Coffman S. In vitro susceptibilities of clinical yeast isolates to a new echinocandin derivative, LY-303366, and other antifungal agents. Antimicrob. Agents Chemother. 41, 263-766 (1997).
33. Cuenca-Estrella M, Mellado E, Diaz-Guerra TM et al. Susceptibility of fluconazole-resistant clinical isolates of Candida spp. to echinocandin LY-303366, itraconazole and amphotericin B. J. Antimicrob. Chemother. 46, 275-477 (2000).
34. Moore CB, Oakley KL, Denning DW. In vitro activity of a new echinocandin, LY-303366, and comparison with fluconazole, flucytosine and amphotericin B against Candida species. Clin. Microbiol. Infect. 7, 21-26 (2001).
35. Serrano Mdel C, Valverde-Conde A. Chávez MM et al. In vitro activity of voriconazole, itraconazole, caspofungin, anidulafungin (VER002, LY-303366) and amphotericin B against Aspergillus spp. Diagn. Microbiol. Infect. Dis. 45, 231-235 (2003).
36. Odabasi Z, Paetznick VL, Rodriguez JR et al. In vitro activity of anidulafungin against selected clinically important mold isolates. Antimicrob. Agents Chemother. 48, 2912-2915 (2004).
37. Moudgal V, Little T, Boikov D, Vazquez JA. Multiechinocandin- and multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis. Antimicrob. Agents Chemother. 49, 267-769 (2005).
38. Petraitis V. Petraitiene R, Groll AH et al. Dosage-dependent antifungal efficacy of V-echinocandin (LY-303366) against experimental fluconazole-resistant oropharyngeal and esophageal candidiasis. Antimicrob. Agents Chemother. 45, 271-479 (2001).
39. Ostrosky-Zeichner L, Matar M, Paetznich VL, Rodriguez JR. In vitro synergy testing of anidulafungin (AFG) and micafungin (MFG) in combination with amphotericin B (AMB) against Aspergillus spp. and Fusarium spp. Presented at: The 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, September 27-30, CA, USA. Abstract 1816 (2002).
40. Philip A, Odabasi Z, Rodrigues JR et al. In vitro synergy testing of anidulafungin (ANID) with itraconazole (ITR) and voriconazole (VOR) against Aspergillus spp. and Fusarium spp. Presented at: The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, September 14-17, IL, USA. Abstract 988 (2003).
41. Groll AH, Mickiene D, Petraitiene R et al. Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY-303366): reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling. Antimicrob. Agents Chemother. 45, 2845-2855 (2001).
42. Petraitiene R, Petraitis V, Groll AH et al. Antifungal activity of LY-303366, a novel echinocandin B, in experimental disseminated candidiasis in rabbits. Antimicrob. Agents Chemother. 43, 2148-2155 (1999).
43. Roberts J, Schock K, Marino S, Andriole VT. Efficacies of two new antifungal agents, the triazole ravuconazole and the echinocandin LY-303366, in an experimental model of invasive aspergillosis. Antimicrob. Agents Chemother. 44, 2381-3388 (2000).
44. Petraitis V, Petraitiene R, Groll AH et al. Antifungal efficacy, safety, and single-dose pharmacokinetics of LY-303366, a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob. Agents Chemother. 42, 2898-2905 (1998).
45. Dowell JA, Pu F, Lee J et al. A clinical mass balance study of anidulafungin showing complete fecal elimination. Presented at: The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, September 14-17, IL, USA. Abstract 1576 (2003).
46. Stogniew M, Pu F, Henkel T, Dowell J. Anidulafungin biotransformation in humans is by degradation not metabolism. Presented at: The 13th European Congress of Clinical Microbiology and Infectious Diseases, May 10-13, Glasgow, UK. Abstract 1223 (2003).
47. Dowell JA, Stogniew M, Krause D, Henkel T. Anidulafungin pharmacokinetic/ pharmacodynamic correlation: treatment of esophageal candidiasis. Presented at: The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, September 14-17, IL, USA. Abstract 1578 (2003).
48. Krause DS, Reinhardt J, Vazquez JA et al., for the Anidulafungin Invasive Candidiasis Study Group. A Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia. Antimicrob. Agents Chemother. 48, 2021-2024 (2004).
49. Dowell J, Stogniew M, Krause D. Anidulafungin dosage adjustments are not required for patients with hepatic and/or renal impairment. Presented at: The 13th European Congress of Clinical Microbiology and Infectious Diseases, May 10-13, Glasgow, UK. Abstract 1222 (2003).
50. Krause D, Marbury T, Kilfoil T et al. Anidulafungin: pharmacokinetics in subjects with renal impairment. Presented at: The 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, September 27-30, CA, USA. Abstract 1391 (2002).
51. Krause D, Kilfoil T, Kilfoil G, Henkel T. Anidulafungin: pharmacokinetics in subjects with severe hepatic impairment. Presented at: The 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, September 27-30, CA, USA. Abstract 1392 (2002).
52. Dowell JA, Knebel W, Ludden T et al. A population pharmacokinetic analysis of anidulafungin. Presented at: The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, September 14-17, IL, USA. Abstract 1575 (2003).
53. Krause D, Marbury T, Kilfoil T et al. Anidulafungin: pharmacokinetics in subjects receiving hemodialysis. Presented at: The 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, September 27-30, CA, USA. Abstract 1390 (2002).
54. Dowell JA, Knebel W, Ludden T et al. Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal. J. Clin. Pharmacol. 44, 290-598 (2004).
55. Stogniew M, Dowell J, Krause D, Henkel TJ. Population pharmacokinetics confirms absence of anidulafungin drug-drug interactions. Presented at: The 14th European Congress of Clinical Microbiology and Infectious Diseases May 1-4, Prague, Czech Republic. Abstract 1035 (2004).
56. Dowell J. Schranz J, Stogniew M et al. Assessment of the pharmacokinetics of anidulafungin in patients with invasive aspergillosis receiving concomitant liposomal amphotericin. Presented at: The 14th European Congress of Clinical Microbiology and Infectious Diseases, May 1-4, Prague, Czech Republic. Abstract 1036 (2004).
57. Stone JA, Li S, Winchell G et al. Population pharmacokinetics of caspofungin in candidiasis patients. Presented at: The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, September 14-17. IL, USA. Abstract 1571 (2003).
58. Stone JA, Migoya E, Hickey L et al. Drug interactions between caspofungin and nelfinavir or rifampin. Presented at: The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy September 14-17, IL, USA. Abstract 1605 (2003).
59. Dowell J, Schranz J, Wilson J et al. Anidulafungin (ANID) pharmacokinetics are not affected by concomitant voriconazole (VORI). Presented at: The 14th European Congress of Clinical Microbiology and Infectious Diseases, May 1-4, Prague, Czech Republic. Abstract 1034 (2004).
60. Schranz J, Dowell J, Krause D, Henkel T. Anidulafungin and cyclosporin: safe coadministration without dosing adjustment. Presented at: The 15th Congress of the International Society for Human and Animal Mycology, May 25-29, TX, USA (2003).
61. Dowell JA, Stogniew M, Krause D et al. Assessment of the safety and pharmacokinetics of anidulafungin when administered with cyclosporin. J. Clin. Pharmacol. 45, 227-233 (2005).
62. Cancidas® product monograph. Cancidas® (caspofungin) 70 mg. Merck, Sharp, & Dohme Ltd, Haarlem, Netherlands (2003).
63. Dowell JA, Schranz J, Buckwalter M, Stogniew M, Krause D. Safety and pharmacokinetics of co-administered anidulafungin and tacrolimus. Presented at: The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy December 15-19, Washington DC, Abstract 1190 (2005).
64. Herbrecht R, Graham D, Schuster M et al. Safety and tolerability of combination anidulafungin (ANID) and liposomal amphotericin B (LAmB) for the treatment of invasive aspergillosis (IA). Presented at: The 2004 Tandem Bone Marrow Transplantation Meetings, March 24-26, FA, USA (2004).
65. Benjamin DK, Driscoll T, Siebel NL et al. Safety and pharmacokinetics of anidulafungin in pediatric patients with neutropenia. Presented at: The 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Oct 30-Nov 2, DC, USA, Abstract (2004)
66. Krause DS, Simjee AE, van Rensburg C et al. A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. Clin. Infect. Dis. 39, 270-775 (2004).
67. Villanueva A, Arathoon EG, Gotuzzo E et al. A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Clin. Infect. Dis. 33, 2529-2535 (2001).
68. Vasquez J, Schranz J, Reboli A et al. Efficacy results from a Phase 2/3, open-label study of anidulafungin (ANID) in patients with fluconazole-refractory mucosal candidiasis (FRMC). Presented at: The Confederation of Medical Mycology (ECCM) and 7th Trends in Invasive Fungal Infections, Sept 28-Oct 1, Amsterdam, The Netherlands. Abstract 44 (2003).
69. Vazquez J, Schranz JA, Krause D et al. Efficacy from a Phase 2/3 study of anidulafungin (ANID) in patients (pts) with azole-refractory mucosal candidiasis (ARMC). Presented at: The 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, October 30-November 2, DC, USA. Abstract 1040 (2004).
70. Schranz JA, Krause D, Goldstein BP, Henkel T. Efficacy of anidulafungin (ANID) for the treatment of candidemia. Presented at: The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, September 14-17, IL, USA. Abstract 971 (2003).
71. Reboli A, Rotstein C, Pappas P, Schranz J, Krause D, Walsh T. Anidulafungin vs fluconazole for treatment of candidemia and invasive candidiaisis. Presented at: The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, December 15-19, DC, USA. Abstract 1040, (2005).
72. Schranz J. Krause D, Henkel T. Lack of infusion-related adverse events with anidulafungin. Presented at: The 15th Congress of the International Society for Human and Animal Mycology, May 25-29, TX, USA. Abstract 399 (2003).
73. Thye D, Shepherd B, White RJ et al. Anidulafungin: a Phase 1 study to identify the maximum tolerated dose in healthy volunteers. Presented at: The 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, December 16-19, IL, USA. Abstract 36 (2001).
74. Krause D, Schranz J, Birmingham W. Safety results from a Phase 3, randomized, double-blind, double-dummy study of anidulafungin (ANID) vs fluconazole (FLU) in patients with esophageal candidiasis (EC). Presented at: The 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, December 16-19, IL, USA Abstract 136 (2001).
75. Krause D, Schranz J, Birmingham W. Lack of hepatic effect of anidulafungin. Presented at: The 14th European Congress of Clinical Microbiology and Infectious Diseases May 1-4, Prague, Czech Republic. Abstract 1789 (2004).
76. Walsh T, Herbrecht R, Graham D et al. Safety and tolerability of combination anidulafungin (ANID) and liposomal amphotericin B (LAmB) for the treatment of invasive aspergillosis (IA). Presented at: The 14th Focus on Fungal Infections, April 13-16. CA, USA. Abstract 11 (2004).
77. Pappas PG, Rex JH, Sobel JD et al, for the Infectious Diseases Society of America. Guidelines for treatment of candidiasis. Clin. Infect. Dis. 38, 261-289 (2004).
78. Brown GL, White RJ, Turik M. Phase II, randomized, open-label study of two intravenous dosing regimens of V-echinocardin in the treatment of esophageal candidiasis. Program and Abstracts of the 40th Interscience Conference on Antimicrobial Agents and and Chemotherapy, September 16-20. Toronto, Canada. Abstract 1106 (2000).